Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types.
Patrick G PiliéVirginia GiulianiWei-Lien WangDaniel J McGrailChristopher A BristowNatalie Yan Li NgoiKeith KyewalabyeKhalida M WaniHung LeErick CampbellNora S SanchezDong YangJinesh S GheeyaRohit Vivek GoswamyVijaykumar HollaKenna Rael ShawFunda Meric-BernstamChiu-Yi LiuXiaoYan MaNingping FengAnnette A MachadoJennifer P BardenhagenChristopher P VellanoJoseph R MarszalekEeson RajendraDesiree PiscitelloTimothy I JohnsonMaria LikhatchevaElias ElinatiJayesh MajithiyaJoana NevesVera GrinkevichMarco RanzaniMarina Roy LuzarragaMarie BoursierLucy ArmstrongLerin GeoGiorgia LilloWai Yiu TseAlexander J F LazarEdmund S KopetzMary K Geck DoSarah LivelyMichael G JohnsonHelen M R RobinsonGraeme C M SmithChristopher L CarrollMaria Emilia Di FrancescoPhilip JonesTimothy P HeffernanTimothy Anthony YapPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These data help to better define ATM LOF across tumor types in order to optimize patient selection and improve molecularly targeted therapeutic approaches for patients with ATM LOF cancers.